MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

Search

Prothena Corp PLC

Затворен

СекторЗдравеопазване

6.4 0.16

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.32

Максимум

6.48

Ключови измерители

By Trading Economics

Приходи

-2.2M

-60M

Продажби

705K

2.8M

Марж на печалбата

-2,128.536

Служители

163

EBITDA

-682K

-65M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+242.81% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-400M

346M

Предишно отваряне

6.24

Предишно затваряне

6.4

Настроения в новините

By Acuity

84%

16%

355 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Prothena Corp PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.07.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FCC Approves U.S. Cellular Sale to T-Mobile

11.07.2025 г., 17:28 ч. UTC

Значими двигатели на пазара

SharpLink Gaming Gains on Ethereum Purchase

11.07.2025 г., 16:57 ч. UTC

Печалби

BASF Cuts Outlook on Global Economy Uncertainty

13.07.2025 г., 23:54 ч. UTC

Пазарно говорене

Oil Edges Higher Amid Supply Disruption Worries -- Market Talk

13.07.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

13.07.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.07.2025 г., 23:40 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

13.07.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Advances Amid Rising Trade Tensions -- Market Talk

13.07.2025 г., 23:39 ч. UTC

Пазарно говорене

China's Growth Momentum Likely Slowed in 2Q -- Market Talk

13.07.2025 г., 23:16 ч. UTC

Печалби

China Shenhua Energy 1H 2024 Net Was CNY32.8B>1088.HK

13.07.2025 г., 23:16 ч. UTC

Печалби

China Shenhua Energy: Drop in Coal Prices Weighed on Results >1088.HK

13.07.2025 г., 23:16 ч. UTC

Печалби

China Shenhua Energy Sees 1H Net CNY25.6B-Net CNY27.6B >1088.HK

13.07.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.07.2025 г., 23:13 ч. UTC

Пазарно говорене

Ryman Healthcare Could Be Turning a Corner -- Market Talk

13.07.2025 г., 11:00 ч. UTC

Придобивния, сливания и поглъщания

The Private-Equity Maneuver Allowing More Investors to Cash Out -- WSJ

12.07.2025 г., 02:24 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11.07.2025 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11.07.2025 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11.07.2025 г., 18:18 ч. UTC

Пазарно говорене

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11.07.2025 г., 17:35 ч. UTC

Пазарно говорене

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11.07.2025 г., 17:26 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11.07.2025 г., 16:53 ч. UTC

Пазарно говорене

Crude Futures Add to Early Gains -- Market Talk

11.07.2025 г., 16:42 ч. UTC

Печалби

BASF Cuts Outlook on Global Economic Uncertainty

11.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11.07.2025 г., 16:05 ч. UTC

Печалби

BASF Will Publish Half-Year Results on July 30

Сравнение с други в отрасъла

Ценова промяна

Prothena Corp PLC Прогноза

Ценова цел

By TipRanks

242.81% нагоре

12-месечна прогноза

Среден 21.94 USD  242.81%

Висок 81 USD

Нисък 4 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Prothena Corp PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

4

Купи

5

Задържане

1

Продай

Техническа оценка

By Trading Central

N/A / 7.35Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

355 / 376 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.